| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -170.87 M USD | 13.55 M USD | -59.27 M USD | -40.08 M USD | -66.76 M USD | -31.20 M USD |
| Depreciation & Amortization | 1.37 M USD | 100000 USD | 100000 USD | 319000 USD | 213000 USD | 637000 USD |
| Stock-Based Compensation | 22.09 M USD | 14.53 M USD | 9.23 M USD | 5.84 M USD | 19.19 M USD | 2.64 M USD |
| Capital Expenditures | 339000 USD | 563000 USD | 175000 USD | 199000 USD | 1.37 M USD | 917000 USD |
| Cash Flow from Investing | 56.77 M USD | -106.10 M USD | -87.18 M USD | -199000 USD | -66.48 M USD | -917000 USD |
| Cash Flow from Financing | 104.60 M USD | 72.40 M USD | 6.90 M USD | 190.73 M USD | 614000 USD | 408.51 M USD |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -171.21 M USD | 12.98 M USD | -59.44 M USD | -40.28 M USD | -68.13 M USD | -32.11 M USD |
Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.